Our findings suggest that HPV+ cervical cancer cells display greater resistance to cisplatin compared to HPV-cells, whilst an increased sensitivity to EZH2 inhibitor EPZ6438 was indicated in vitro. Here, EZH2 is linked to cervical carcinoma.